MedPath

Victor Ambros and Gary Ruvkun Awarded Nobel Prize for microRNA Discovery

• Victor Ambros and Gary Ruvkun have been awarded the Nobel Prize in Physiology or Medicine for their discovery of microRNA and its role in gene regulation. • MicroRNAs are small RNA molecules crucial for controlling gene expression and are essential for multicellular organisms, including humans. • The discovery has opened new avenues for treating diseases like cancer by modulating gene activity at the cellular level, with clinical trials underway. • Their work has solved a decades-old mystery and provided a new way of developing medicines by controlling the activity of genes altered in diseases.

The 2024 Nobel Prize in Physiology or Medicine has been awarded to American scientists Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNA (miRNA) and its fundamental role in gene regulation. This breakthrough has revolutionized the understanding of how genes function at the cellular level and opened potential new avenues for treating diseases, particularly cancer.
The Nobel Assembly at the Karolinska Institute recognized that Ambros and Ruvkun's work has proven to be fundamentally important in understanding how organisms develop and function. Their research, conducted independently but collaboratively, focused on the roundworm C. elegans to investigate cell mutations and their timing. This led to the identification of microRNAs, a novel class of small RNA molecules that regulate gene expression by selectively instructing cells.
"The seminal discovery of microRNA has introduced a new and unexpected mechanism of gene regulation," said Thomas Perlmann, Secretary-General of the Nobel Assembly. He added that microRNAs are crucial for understanding embryological development, normal cell physiology, and diseases such as cancer.
MicroRNAs function by altering how genes in the cell operate. Dr. Claire Fletcher, a lecturer in molecular oncology at Imperial College London, explained that in diseases like cancer, where a particular gene might be overactive or mutated, microRNAs can be delivered to cancer cells to halt the mutated gene's effect. This offers a new approach to drug development and biomarker discovery.
Currently, clinical trials are underway to explore the potential of microRNA-based therapies, particularly in treating skin cancer, and also cardiovascular and kidney diseases. While no microRNA-based drug treatments have yet been approved by drug regulators, experts anticipate potential approvals within the next five to ten years.
Gary Ruvkun, a professor of genetics at Harvard Medical School, expressed his excitement upon receiving the news, stating, "It's quite a sea change." Victor Ambros, a professor of natural science at the University of Massachusetts Medical School, also shared his astonishment and delight.
The Nobel Prize includes a cash award of 11 million Swedish kronor ($1 million), a diploma, and a gold medal. The laureates will receive their awards at a ceremony on December 10 in Stockholm.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Reference News

[1]
US scientists win Nobel Prize for gene regulation breakthrough - Punch Newspapers
punchng.com · Oct 7, 2024

Victor Ambros and Gary Ruvkun won the Nobel Prize in Medicine for discovering microRNA's role in gene regulation, essent...

[2]
Nobel Prize in medicine honors American duo for their discovery of microRNA
nypost.com · Oct 7, 2024

Victor Ambros and Gary Ruvkun won the Nobel Prize in physiology or medicine for discovering microRNA, which regulate gen...

© Copyright 2025. All Rights Reserved by MedPath